ClinicalTrials.Veeva

Menu
P

Preferred Primary Care Physicians | Pittsburgh, PA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Erenumab
Semaglutide
LY3298176
Canakinumab
Galcanezumab
Eluxadoline
ABP-450
Bococizumab
Atogepant
Tirzepatide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 35 total trials

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The st...

Enrolling
Diabetes Mellitus, Type 2
Drug: Trizepatide
Drug: NNC0519-0130

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study interventi...

Invitation-only
Irritable Bowel Syndrome
Drug: 25mg Eluxadoline
Drug: 100mg Eluxadoline

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide
Locations recently updated

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide
Locations recently updated

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling
Migraine
Drug: Erenumab Dose 3
Drug: Erenumab Dose 1
Locations recently updated

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling
Migraine
Drug: Erenumab Dose 2
Drug: Erenumab Dose 3

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatmen...

Active, not recruiting
Migraine
Drug: Placebo comparator dosing
Drug: Rimegepant 75mg every other day dosing

The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints f...

Enrolling
Type 2 Diabetes
Device: Duodenal Mucosal Resurfacing (Sham)
Device: Duodenal Mucosal Resurfacing (DMR)

This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine...

Invitation-only
Migraine
Drug: ABP-450

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per m...

Active, not recruiting
Migraine
Drug: ABP-450
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D)...

Enrolling
Irritable Bowel Syndrome
Drug: Eluxadoline
Drug: Placebo

Trial sponsors

Lilly logo
Pfizer logo
Allergan logo
Amgen logo
Novo Nordisk logo
A
AbbVie logo
Novartis logo
Boehringer Ingelheim logo
Enanta Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems